ESMO 2023 BioNTech Data
BNT211 ESMO Data: Key Takeaway Messages
Safety: Toxicities at higher dose level led to further evaluation of safety via
backfilling into several cohorts
Efficacy: Encouraging signs of activity with 13 responses in 22 evaluable
patients at DL2 (ORR 59%, DCR 95%)
Pharmacokinetics: CARVac improved CAR-T persistence, leading to
sustained, ongoing detection up to 100 days in several patients at DL2
Outlook: Backfilling to determine RP2D for CLDN6 CAR-T cells for a pivotal
trial in GCT is currently ongoing
CAR chimeric antigen receptors; CARVac = CAR T-cell amplifying RNA vaccine; CLDN6 = claudin-6; DCR disease control rate; DL dose level; GCT = germ cell tumor; ORR = objective response rate; RPD2 = recommended Phase II dose.
19
BIONTECHView entire presentation